We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-21.35%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$2.43B
AUM Growth
-$314M
Cap. Flow
-$88.1M
Cap. Flow %
-3.63%
Top 10 Hldgs %
48.1%
Holding
447
New
130
Increased
120
Reduced
90
Closed
66

Top Sells

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$28.9M
2
MRK icon
Merck
MRK
+$17.9M
3
XOM icon
ExxonMobil
XOM
+$14.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$13.4M
5
LPCN icon
Lipocine
LPCN
+$7.13M

Sector Composition

Rank Sector Weight
1 Healthcare 13.39%
2 Energy 1.08%
3 Technology 0.46%
4 Materials 0.45%
5 Consumer Discretionary 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PGEN icon
301
PUT
Precigen
PGEN
$1.98B
$426K 0.02%
135
+44
+48% +$2.15K
MACK
302
CALL
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$426K 0.02%
+64
New +$5.22K
QURE icon
303
PUT
uniQure
QURE
$2.72B
$425K 0.02%
+208
New +$5.48K
NVRO
304
DELISTED
NEVRO CORP.
NVRO
$421K 0.02%
+9,066
New +$439K
CARM
305
DELISTED
Carisma Therapeutics
CARM
$413K 0.02%
+8,577
New +$529K
IMUX icon
306
PUT
Immunic
IMUX
$180M
$404K 0.02%
+3
New +$15K
RMTI icon
307
PUT
Rockwell Medical
RMTI
$26.1M
$381K 0.02%
4
AERI
308
CALL
DELISTED
Aerie Pharmaceuticals
AERI
$381K 0.02%
+215
New +$3.89K
CYTR
309
DELISTED
CytRx Corp
CYTR
$378K 0.02%
+26,597
New +$451K
ACGN
310
PUT
DELISTED
Aceragen Inc
ACGN
$372K 0.02%
8
+6
+300% +$2.65K
RMTI icon
311
Rockwell Medical
RMTI
$26.1M
$358K 0.01%
422
+261
+162% +$378K
AFMD
312
DELISTED
Affimed
AFMD
$350K 0.01%
+5,677
New +$703K
GMED icon
313
Globus Medical
GMED
$10.9B
$345K 0.01%
+16,700
New +$423K
PRQR icon
314
ProQR Therapeutics
PRQR
$247M
$320K 0.01%
21,950
-61,050
-74% -$1.02M
ZLTQ
315
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$320K 0.01%
+10,000
New +$331K
PTCT icon
316
PUT
PTC Therapeutics
PTCT
$6.23B
$318K 0.01%
119
OXGN
317
DELISTED
OXIGENE INC COM
OXGN
$305K 0.01%
328,431
+69,996
+27% +$91.2K
TLPH icon
318
Talphera
TLPH
$67M
$301K 0.01%
4,930
-2,205
-31% -$181K
NSPH
319
DELISTED
NANOSPHERE INC. COM NEW
NSPH
$297K 0.01%
181,946
+12,915
+8% +$33.4K
BHC icon
320
PUT
Bausch Health
BHC
$1.68B
$285K 0.01%
16
-69
-81% -$16.1K
LXRX icon
321
PUT
Lexicon Pharmaceuticals
LXRX
$1.03B
$279K 0.01%
+260
New +$2.84K
HSTO
322
DELISTED
Histogen Inc. Common Stock
HSTO
$278K 0.01%
313
-1,554
-83% -$1.42M
PVLA
323
Palvella Therapeutics
PVLA
$2.07B
$276K 0.01%
+1,884
New +$420K
SIOX
324
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$272K 0.01%
+2,632
New +$309K
RPTP
325
PUT
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$264K 0.01%
436
-594
-58% -$7.28K

Similar funds

Sabby Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sabby Management held 447 positions worth $2.43B, down 11% from $2.74B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sabby Management withdrew a net $88.1M in Q3 2015, closing 66 positions and reducing 90 holdings. Its most notable exit was iShares 20+ Year Treasury Bond ETF, an estimated $28.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 13% of assets, up from 8.3% a quarter earlier, followed by Energy and Technology.

Against the trend, Sabby Management opened a new position in iShares Russell 2000 ETF worth $35.7M.

  • Sabby Management's largest Q3 2015 buy was iShares Russell 2000 ETF: 327,168 shares worth $35.7M.
  • Sabby Management added most to Mobileye N.V. in Q3 2015, an estimated $8.9M increase.
  • Sabby Management's biggest Q3 2015 reduction was Lipocine, cutting an estimated $7.13M.
  • Sabby Management fully exited iShares 20+ Year Treasury Bond ETF in Q3 2015, selling an estimated $28.9M.
  • Sabby Management's ten largest holdings make up 48% of its $2.43B portfolio in Q3 2015.
  • Sabby Management opened 130 new positions and closed 66 in Q3 2015.
  • Sabby Management's portfolio value fell 11% quarter-over-quarter to $2.43B.

Based on Sabby Management's 13F filing for Q3 2015, filed 16 Nov 2015.